Cutaneous Manifestations of Parvovirus B19: A Quick Review in the Wake of the Recent Outbreak Across Various Regions

Dear Editor, The Centers for Disease Control and Prevention (CDC) has issued an advisory in response to a significant increase in human Parvovirus B19 activity across the United States, particularly among children aged five to nine years.[1] This surge is part of a broader trend observed in the first quarter of 2024, where public health authorities in 14 European countries also reported unusually high numbers of cases. Similarly, a recent study from Tamil Nadu, India, highlighted concerning findings, with nearly one-fourth of healthy blood donors testing positive for anti-Parvovirus B19 IgM antibodies.[2] The outbreak is particularly alarming due to the virus's high transmission rate through respiratory droplets and its potential to cause severe complications in vulnerable populations, including pregnant individuals, those with immunocompromising conditions, and people with chronic hemolytic disorders. Given the absence of routine surveillance for Parvovirus B19, this escalating situation emphasizes the urgent need for heightened awareness and prompt diagnosis. The recognition of cutaneous manifestations in Parvovirus B19 infection is critical for diagnosis, particularly given the nonspecific nature of the early systemic symptoms. The infection usually follows a biphasic course. The initial phase, approximately seven days postinfection, is characterized by fever, myalgia, and malaise, during which the individual is highly infectious due to elevated viral loads. The subsequent phase, occurring seven to ten days later, presents with more distinct dermatological signs. In pediatric patients, this includes the pathognomonic erythema infectiosum/ fifth disease, or "slapped cheek" rash, often followed by a reticulated rash on the limbs and trunk [Figure 1].Figure 1: "Slapped cheek" appearance in a child with erythema infectiosumIn adults, cutaneous rashes are among the most common clinical features, occurring in 50–60% of symptomatic cases, along with symmetrical polyarthralgia and fever. This infection is particularly common among young women. Nonspecific maculopapular and purpuric rashes are variably reported as the most prevalent types of skin manifestations. These cutaneous manifestations commonly appear after the viral load has declined, indicating that the patient is no longer contagious. However, their presence still holds epidemiologic importance, as it can raise clinical suspicion in those recently exposed, aiding in early diagnosis and timely intervention [Figure 2].Figure 2: Schematic representation of Parvovirus B19 transmission and clinical progression (This figure was generated using ChatGPT's image generation tool (OpenAI, 2024) based on the authors' inputs. It is original, created specifically for this manuscript, and free of copyright restrictions)Another characteristic presentation of Parvovirus B19 is papular—purpuric gloves and socks syndrome (PPGSS), which predominantly affects adolescents and adults. This syndrome is characterized by marked edema of the hands and feet, particularly involving the palms and soles, accompanied by petechiae and purpura, with a sharp demarcation at the wrists and ankles. Crucially, PPGSS typically arises while the patient is still viremic and therefore contagious, imparting distinct epidemiologic implications. Beyond PPGSS, various purpuric manifestations documented in association with Parvovirus B19 in adults include thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, leukocytoclastic vasculitis, Henoch–Schönlein purpura, asymmetrical/ symmetrical periflexural petechiae, and nonspecific purpura.[3] When encountering an adult patient with fever, a purpuric rash (whether palpable or nonpalpable), and arthralgia; Parvovirus B19 should be considered in the differential diagnosis. Additionally, isolated cutaneous manifestations linked to Parvovirus B19 have been reported such as palmoplantar desquamation, nonspecific pruritus, erythema nodosum, erythema multiforme, angioedema, vesicular lesions, livedo reticularis, and Degos-like lesions.[4] Lesions resembling cutaneous lupus, dermatomyositis, and Sweet's syndrome have also been reported.[5] Familiarity with these less common dermatological findings can assist clinicians in identifying Parvovirus B19 infection in patients presenting with other compatible clinical symptoms, especially in the setting of an outbreak. Table 1 provides a summary of the common clinical presentations of Parvovirus B19 and highlights key differential diagnoses.Table 1: Common clinical presentations and differential diagnoses of Parvovirus B19 related rashIn conclusion, we highlight the importance of recognizing the diverse cutaneous manifestations of Parvovirus B19 as key diagnostic indicators, especially during outbreaks like the current one. Understanding dermatological signs is crucial for establishing an early diagnosis and framing important differentials in a setting of a suspected viral infection, especially in the wake of the recent outbreaks of dengue in the United States and Mpox in Congo. Promptly identifying these manifestations should guide appropriate clinical decisions such as ordering viral DNA and serological assays, ultimately enhancing outcomes in susceptible patient populations via required screening, vigilance, and monitoring. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest. Use of artificial intelligence (AI) This manuscript was written entirely by the authors. However, generative AI (ChatGPT, OpenAI, 2024) was used solely to assist in the conceptualization and graphic generation of Figure 2. The final content, data interpretation, and manuscript writing were conducted and verified entirely by the authors.